FHTX logo

FHTX Foghorn Therapeutics Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.00
-0.09 (-4.31%)

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system.…

Market Cap: $118.77Mfoghorntx.com

Price

No data yet.

Social Signal Score

46
5d
—
30d
65
2 mentions
—
60d
36
6 mentions
—
90d
38
7 mentions
—
news: 7

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 4Sell 0Strong Sell 0
Avg price target$4+100.0%
Low $2Median $5High $5
Current Consensus

Revenue

$83.54M
$0.00$27.85M$55.70M$83.54M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-1.11
$-1.16–$-1.05
7 analysts
FY2026
$-0.08
$-0.16–$0.03
6 analysts
FY2027
$-0.99
$-1.28–$-0.65
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Adrian H. Gottschalk
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
3.21
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
-2.54
foghorntx.com